Medtronic received FDA clearance for the Stealth AXiS surgical system for cranial and ENT procedures, enabling U.S. commercialization. The clearance bolsters Medtronic's surgical navigation/robotics portfolio and should provide a modest multi-year revenue and procedure-share tailwind for its neurosurgery and ENT franchises.
Medtronic received FDA clearance for the Stealth AXiS surgical system for cranial and ENT procedures, enabling U.S. commercialization. The clearance bolsters Medtronic's surgical navigation/robotics portfolio and should provide a modest multi-year revenue and procedure-share tailwind for its neurosurgery and ENT franchises.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
